AN INTEGRATED APPROACH UTILIZING LARGE-SCALE CHEMICAL SCREENS TO IDENTIFY THERAPEUTIC AGENTS AGAINST TUMOR INITIATING CELLS DERIVED FROM INDIVIDUAL PATIENTS. CANDIDATES ARE EVALUATED IN VIVO IN MATCHING PATIENT-DERIVED XENOGRAFT MODELS TO ALLOW PATIENT-SPECIFIC THERAPEUTIC AGENTS.

PI: Greg D. Foltz, M.D.
Director, The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment
Swedish Medical Center